(SITC) Annual Meeting 20206 Nov 2020 11:06
So next week at SITC we get 1st time reporting of:
1. Initial data of how MRx0518 enhances the body's immune response against cancer.
2. Safety data
3. data on using MRx0518 as a single therapy prior to a main treatment for cancer
4. data on how MRx0518 takes advantage of the body's immune system to fight cancer
5. Update on phase A part of the study.
"Having been a clinical investigator on over 150 early stage trials with a wide variety of anti-cancer agents, I believe that these results are extremely encouraging, particularly given the novelty of the approach and the durability of clinical benefit observed."
"This is ground-breaking for the microbiome in immuno-oncology. Considering the advanced stage of disease of the patients in the study, end of line patients who have previously failed on a checkpoint inhibitor and have little to no remaining treatment options, these results are very promising."
"We believe that, while this is a small study, these efficacy and safety results in such a difficult-to-treat population are notable. To achieve these results while maintaining a very clean safety profile is to our knowledge unparalleled, and particularly significant in oncology where there is all too often the unfortunate trade-off between treatment and quality of life, and patients often elect to interrupt or stop treatment completely due to adverse side effects."
ALL LOOK VERY BULLISH FOR NEXT WEEK !...;O))